‘Artificial Pancreas Dashboard' can help standardize hybrid closed-loop reporting

A standardized "Artificial Pancreas (AP) Dashboard" should provide easy to use single-page hybrid closed-loop system (HCL) reporting for insulin-requiring patients with diabetes. The AP Dashboard will help standardize HCL reporting similar to standardized CGM reporting and an electrocardiogram (EKG) and will be likely to help improve glycemic control and reduce hypoglycemia.

It is described in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT). Click here to read the article now.

The developers of the AP Dashboard concept propose a single-page report comprised of seven main components. These provide detailed information and visualization of glucose, insulin, and HCL-specific metrics. They include glucose metrics, hypoglycemia, insulin, user experience, hyperglycemia, glucose modal-day profile, and insight.

Each main component may be divided into subcomponents. For example, glucose metrics include four variables: mean glucose; standard deviation; glucose management indicator; and a visual graph displaying the recommended continuous glucose monitor metrics, such as time-in-range, time-above-range, and time-below-range.

The recommendations also include the optimal sampling duration for HCL data download and color coding for visualization ease.

Successful use of an HCL system requires interpretation of the glucose and insulin metrics and optimization of HCL settings."

Viral Shah, MD, Satish Garg, MD, Study Co-Authors, University of Colorado Anschutz Medical Campus

"We believe it is time to standardize the terminology and reporting of different HCL systems. We recommend various HCL metrics and visualizations for a standardized HCL reporting similar to an EKG. We realize that this is only a starting point and fully understand that this can and will be improved with others' input."

Source:
Journal reference:

Shah, V, N & Garg, S, K. (2020) Standardized Hybrid Closed-Loop System Reporting. Diabetes Technology & Therapeutics. doi.org/10.1089/dia.2020.0622.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease